Two anti-hEGFR mAbs, cetuximab (chimeric human/mouse IgG1) and panitumumab (human IgG2), have been approved for the treatment of CRC with KRAS wild-type tumors [16,28]. The gene discussed is KRAS; the disease is colorectal carcinoma.